Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer.
Schoch had served as interim CFO since January 2024 and is being elevated to the permanent position, the company said on Monday.
“Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO,” Candel CEO Dr Paul Peter Tak said in a statement.
“He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management.”
Schoch joined Candel in November 2021 and has held multiple titles, most recently serving as senior vice president following a January 2025 promotion. During his time with the company, he has led key initiatives, including Candel’s financial reporting, internal controls, and investor-facing efforts.
As interim CFO, Schoch played a critical role in securing a capital raise of approximately $86 million, following the release of positive Phase 3 results for the company’s lead asset, CAN-2409, in localized prostate cancer, the company highlighted.
Before joining Candel, Schoch held senior finance roles at Corbus Pharmaceuticals and spent seven years with PwC’s Health Industry assurance practice, serving clients across the life sciences spectrum.
Schoch expressed excitement about the appointment and the opportunities ahead for Candel.
“As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future,” he said.
“I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need.”